Ignite Creation Date:
2024-05-06 @ 7:24 PM
Last Modification Date:
2024-10-26 @ 3:06 PM
Study NCT ID:
NCT05994768
Status:
COMPLETED
Last Update Posted:
2023-11-30
First Post:
2023-08-09
Brief Title:
18F-FDG Tomography and Labeled Leukocyte Scintigraphy
Sponsor:
Central Hospital Nancy France
Organization:
Central Hospital Nancy France
Study Overview
Official Title:
Comparison of the Performance of 18F-FDG PETCT With That of Labeled Leukocyte Scintigraphy in the Follow-up of Malignant Otitis Externa
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OEN
Brief Summary:
The study will aim to show that there is a superiority of 18F-FDG PETCT compared to labeled leukocyte scintigraphy in patients with a malignant otitis externa
Detailed Description:
The management of malignant otitis externa MEO is a major issue in patients who are often polypathological and fragile Appropriate antibiotic therapy must be started quickly after the diagnosis is made and followed for a period of at least 6 weeks Imaging plays a major role in assessing the extent of the infection and especially healing after 6 weeks of antibiotic therapy The persistence of an infection at the end of the treatment observed in imaging will allow a change of antibiotic line This study consists in studying in a population affected by an OEM the performance of PETCT with 18F-FDG compared to scintigraphy with labeled leukocytes The usefulness of the latter in the follow-up of the pathology after antibiotic therapy has already been proven in the literature The study will aim to show that there is a superiority of 18F-FDG PETCT compared to labeled leukocyte scintigraphy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None